Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

7.445 +0.035 (+0.47%)
Streaming Delayed Price Updated: 2:33 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) Near the Top of Equities by Percentage Gain on 11/21
Via Investor Brand Network
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Participate in Investor Conferences in September
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Participate in Two Investor Conferences in May
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Participate in Two Investor Conferences in November
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.